187 related articles for article (PubMed ID: 28442265)
1. Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Lan T; Wang H; Zhang Z; Zhang M; Qu Y; Zhao Z; Fan X; Zhan Q; Song Y; Yu C
Exp Cell Res; 2017 Aug; 357(1):51-58. PubMed ID: 28442265
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Wang Z; Sun J; Li X; Yang S; Yue S; Zhang J; Yang X; Zhu T; Jiang R; Yang W
Oncol Rep; 2013 Apr; 29(4):1395-8. PubMed ID: 23338526
[TBL] [Abstract][Full Text] [Related]
3. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y
Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809
[TBL] [Abstract][Full Text] [Related]
4. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
5. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
6. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
7. Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway.
Dhruv HD; Roos A; Tomboc PJ; Tuncali S; Chavez A; Mathews I; Berens ME; Loftus JC; Tran NL
J Neurooncol; 2016 Feb; 126(3):397-404. PubMed ID: 26559543
[TBL] [Abstract][Full Text] [Related]
8. Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Cheng Q; Ma X; Cao H; Chen Z; Wan X; Chen R; Peng R; Huang J; Jiang B
Mol Med Rep; 2017 Feb; 15(2):597-604. PubMed ID: 28035389
[TBL] [Abstract][Full Text] [Related]
9. MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Yang CH; Wang Y; Sims M; Cai C; He P; Yue J; Cheng J; Boop FA; Pfeffer SR; Pfeffer LM
Oncotarget; 2016 Dec; 7(51):84017-84029. PubMed ID: 27705947
[TBL] [Abstract][Full Text] [Related]
10. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
11. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
12. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines.
Gallo-Oller G; Vollmann-Zwerenz A; Meléndez B; Rey JA; Hau P; Dotor J; Castresana JS
Cancer Lett; 2016 Oct; 381(1):67-75. PubMed ID: 27473823
[TBL] [Abstract][Full Text] [Related]
13. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
15. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
16. PTP4A3 is a target for inhibition of cell proliferatin, migration and invasion through Akt/mTOR signaling pathway in glioblastoma under the regulation of miR-137.
Wang L; Liu J; Zhong Z; Gong X; Liu W; Shi L; Li X
Brain Res; 2016 Sep; 1646():441-450. PubMed ID: 27328425
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Liu YJ; Ma YC; Zhang WJ; Yang ZZ; Liang DS; Wu ZF; Qi XR
Oncotarget; 2017 Jun; 8(26):42495-42509. PubMed ID: 28477008
[TBL] [Abstract][Full Text] [Related]
18. Phostine PST3.1a Targets MGAT5 and Inhibits Glioblastoma-Initiating Cell Invasiveness and Proliferation.
Hassani Z; Saleh A; Turpault S; Khiati S; Morelle W; Vignon J; Hugnot JP; Uro-Coste E; Legrand P; Delaforge M; Loiseau S; Clarion L; Lecouvey M; Volle JN; Virieux D; Pirat JL; Duffau H; Bakalara N
Mol Cancer Res; 2017 Oct; 15(10):1376-1387. PubMed ID: 28634226
[TBL] [Abstract][Full Text] [Related]
19. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.
Guo Y; He X; Zhang M; Qu Y; Gu C; Ren M; Wang H; Ning W; Li J; Yu C; Zhang H
J Neurooncol; 2020 Apr; 147(2):327-337. PubMed ID: 32170633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]